GlassScriptPhysician profile
Kerstin Lorelei Rieg
NPI 1972371508
$1,585.15
in general payments reported to CMS, 2019-2025
23 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $218 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.10 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $204.74 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $143.87 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $139.81 | 2024-2025 | Ozempic |
| Shield Therapeutics INC | $105.96 | 2025 | |
| Neurocrine Biosciences, INC. | $97.20 | 2025 | |
| Sumitomo Pharma America, INC. | $69.72 | 2025 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $60.15 | 2025 | |
| Lilly USA, LLC | $58.22 | 2025 | Zepbound, Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $47.44 | 2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.89 | 2025 | Caplyta |
| Exeltis, USA INC. | $43.94 | 2025 | Slynd |
| Verona Pharma, INC. | $43.23 | 2025 | Ohtuvayre |
| Abbott Laboratories | $38.01 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $36.44 | 2025 | Repatha, Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $23.19 | 2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.92 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $18.97 | 2025 | Bexsero |
| Axsome Therapeutics, INC. | $18.41 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $15.34 | 2024 | M-M-R II, Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $15.20 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.10 | 2025 | Jardiance |
| Organon LLC | $10.30 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerstin Rieg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.